Announcement PDF ASX RELEASE 15 September 2026 Dr Daniel Furtner appointed Chief Medical Officer, Dr Donna Skerrett continues as Senior Scientific Advisor Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to announce the appointment of Dr Daniel Furtner as Chief Medical Officer (CMO), effective Wednesday, 16 September 2026. Dr Furtner succeeds Dr Donna Skerrett, who will remain with the Company as Senior Scientific Advisor, ensuring continuity of scientific expertise as Paradigm advances its global Phase 3 osteoarthritis program. Dr Furtner brings more than 20 years of leadership experience across the life sciences and healthcare industries, with expertise in medical affairs, rheumatology, immunology and joint diseases. His appointment supports Paradigm’s next stage of development as the Company progresses its Phase 3 clinical evidence package for injectable pentosan polysulfate sodium (iPPS; Zilosul®) and prepares for future regulatory submissions. Prior to joining Paradigm, Dr Furtner served as Senior Director of Medical Affairs for the Asia Pacific region at CSL, based in Melbourne. He previously held roles of increasing responsibility at Abbott/AbbVie and Janssen across Europe, Asia and Australia. Throughout his career, he has led international clinical studies and educational programs supporting patients, caregivers and nurses, with a particular focus on advancing rheumatology care in the Asia Pacific region. Dr Furtner holds a Doctor of Medicine from the Medical University of Vienna and completed his medical residency at Klinik Donaustadt and the Lorenz Böhler Trauma Centre in Vienna. He also holds a Master of Business Administration in general management from Danube Business School in Krems, Austria. Dr Skerrett has served as Paradigm’s Chief Medical Officer since September 2019 and has played a central role in the Company’s clinical and regulatory development. Her leadership has been instrumental in the execution of the global Phase 3 PARA_OA_012 trial, which completed recruitment with 538 participants across the United States, Australia, Hong Kong and Moldova. As outlined in Paradigm’s FY26 Annual Report, this leadership transition reflects the program’s progression towards clinical evidence generation and preparation for future regulatory submissions. As Senior Scientific Advisor, Dr Skerrett will continue to contribute her extensive knowledge of iPPS and Paradigm’s development programs, supporting Dr Furtner and the clinical team through the next stage. Paradigm Executive Chairman, Mr Paul Rennie, commented: “On behalf of the Board and the entire Paradigm team, I would like to thank Donna for her outstanding contribution as Chief Medical Officer. Since joining Paradigm in 2019, Donna has helped shape our clinical development strategy and has led our clinical team with an unwavering commitment to scientific rigour, patient safety and data quality. “The successful recruitment of 538 participants into our global Phase 3 trial reflects years of planning, regulatory preparation and clinical execution. Donna’s leadership has been central to that achievement, and we are delighted that she will continue to contribute her expertise as Senior Scientific Advisor. “Daniel brings extensive international pharmaceutical experience and deep therapeutic knowledge in rheumatology and joint diseases. His experience in medical affairs and international clinical studies will be valuable as we advance our Phase 3 program and develop the evidence package to support future regulatory submissions. Having Daniel lead our medical strategy, with Donna’s continued scientific support, provides a strong foundation for this next stage.” Dr Donna Skerrett commented: “Leading Paradigm’s clinical program has been immensely rewarding and completing recruitment into PARA_OA_012 has been one of the proudest achievements of my career. It reflects the extraordinary commitment of our clinical team, investigators, partners and, above all, the participants and their families. “I remain fully committed to Paradigm and excited by the potential of iPPS. I look forward to supporting Daniel through a seamless transition and continuing to contribute as Senior Scientific Advisor as we generate the clinical and scientific evidence that will guide the program’s next steps.” -ENDS- About Paradigm Biopharmaceuticals Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2). Authorised for release by the Paradigm Board of Directors. To learn more please visit: www.paradigmbiopharma.com FOR FURTHER INFORMATION PLEASE CONTACT: Simon White Director of Investor Relations Tel: +61 404 216 467 Paradigm Biopharmaceuticals Ltd. ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA Email: investorrelations@paradigmbiopharma.com